

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CANbridge Pharmaceuticals Inc.

北海康成製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1228)

VOLUNTARY ANNOUNCEMENT

NHIA REIMBURSEMENT APPROVAL OF LIVMARLI® IN TAIWAN

This announcement is made by CANbridge Pharmaceuticals Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to update the shareholders and potential investors of the Company on the latest business development of the Group in relation to the National Health Insurance Administration (“**NHIA**”) reimbursement approval of Livmarli® (Maralixibat Chloride Oral Solution) (“**Livmarli**”) in Taiwan.

The board of directors (the “**Board**”) of the Company is pleased to announce that Livmarli, indicated for the treatment of Alagille Syndrome (“**ALGS**”) and Progressive Familial Intrahepatic Cholestasis (“**PFIC**”), has obtained reimbursement approval from NHIA in Taiwan. The reimbursement coverage will take effect on September 1, 2026.

Livmarli is a minimally absorbed ileal bile acid transporter inhibitor that blocks the enterohepatic circulation of bile acids, reduces bile acid levels in the liver and serum, reduces the resultant liver injury and relieves pruritus (extreme itching). Livmarli is the first medication approved in Mainland China, Hong Kong and the United States (“**U.S.**”) to treat cholestatic pruritus associated with ALGS in patients 3 months of age and older, and also the first medication approved for this indication in the European Union (“**EU**”) and Taiwan region in patients with ALGS 2 months of age and older. In addition, Livmarli is approved in the U.S. for the treatment of cholestatic pruritus in patients with PFIC 12 months of age and older and in the EU, Hong Kong and Taiwan region for the treatment of patients with PFIC 3 months of age and older. Livmarli has been granted Breakthrough Therapy designation for ALGS and PFIC by the U.S. Food and Drug Administration (“**FDA**”), and has obtained orphan drug designation for ALGS and PFIC from the FDA, the European Medicines Agency and the Taiwan Food and Drug Administration.

The Company considers that, as the first approved therapy for ALGS and PFIC in Taiwan, Livmarli gaining NHIA reimbursement approval for both indications marks a significant milestone for patients living with ALGS and PFIC, and such development will immediately and substantially alleviate the financial burden on patient families in Taiwan. The Company looks forward to continuously working with the Taiwan NHIA and the Taiwanese cholestatic pruritus community to allow all eligible patients to gain early access to Livmarli toward achieving optimal improvements in quality of life.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
CANbridge Pharmaceuticals Inc.
Dr. James Qun Xue
Chairman

Hong Kong, August 18, 2026

As of the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director; Ms. Wei Zhao and Mr. Tingwei Wang as non-executive Directors; and Dr. Richard Arthur Moscicki, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.